RESUMEN
Type 1 polyketides are a major class of natural products used as antiviral, antibiotic, antifungal, antiparasitic, immunosuppressive, and antitumor drugs. Analysis of public microbial genomes leads to the discovery of over sixty thousand type 1 polyketide gene clusters. However, the molecular products of only about a hundred of these clusters are characterized, leaving most metabolites unknown. Characterizing polyketides relies on bioactivity-guided purification, which is expensive and time-consuming. To address this, we present Seq2PKS, a machine learning algorithm that predicts chemical structures derived from Type 1 polyketide synthases. Seq2PKS predicts numerous putative structures for each gene cluster to enhance accuracy. The correct structure is identified using a variable mass spectral database search. Benchmarks show that Seq2PKS outperforms existing methods. Applying Seq2PKS to Actinobacteria datasets, we discover biosynthetic gene clusters for monazomycin, oasomycin A, and 2-aminobenzamide-actiphenol.
Asunto(s)
Espectrometría de Masas , Familia de Multigenes , Sintasas Poliquetidas , Policétidos , Policétidos/metabolismo , Policétidos/química , Sintasas Poliquetidas/genética , Sintasas Poliquetidas/metabolismo , Espectrometría de Masas/métodos , Minería de Datos/métodos , Aprendizaje Automático , Actinobacteria/genética , Actinobacteria/metabolismo , Genoma Bacteriano , Algoritmos , Productos Biológicos/química , Productos Biológicos/metabolismoRESUMEN
Discovery and structure elucidation of natural products available in infinitesimally small quantities are recognized challenge. This challenge is epitomized by the diphenazine class of molecules that contain three bridged stereocenters, several conformations, ring fusions, and multiple spatially isolated phenols. Because empirical NMR and spatial analyses using ROESY/NOESY were unsuccessful in tackling these challenges, we developed a computational pipeline to determine the relative and absolute configurations and phenol positions of diphenazines as inhibitors of eukaryotic translation initiation factor 4E (eIF4E) protein-protein interactions. In this pipeline, we incorporated ECD and GIAO NMR calculations coupled with a DP4+ probability measure, enabling the structure revision of phenazinolin D (4), izumiphenazine A (5), and baraphenazine G (7) and the structure characterization of two new diphenazines, baraphenazine H (3) and izumiphenazine E (6). Importantly, through these efforts, we demonstrate the feasibility of NMR/DP4+ analysis for the determination of phenol positions in phenazine-based molecules, further expanding the limits of computational methods for the structure elucidation of complex natural products.
Asunto(s)
Productos Biológicos , Estructura Molecular , Productos Biológicos/química , Fenol , Espectroscopía de Resonancia MagnéticaRESUMEN
Gyromitrin (acetaldehyde N-methyl-N-formylhydrazone) and its homologs are deadly mycotoxins produced most infamously by the lorchel (also known as false morel) Gyromitra esculenta, which is paradoxically consumed as a delicacy in some parts of the world. There is much speculation about the presence of gyromitrin in other species of the lorchel family (Discinaceae), but no studies have broadly assessed its distribution. Given the history of poisonings associated with the consumption of G. esculenta and G. ambigua, we hypothesized that gyromitrin evolved in the last common ancestor of these taxa and would be present in their descendants with adaptive loss of function in the nested truffle clade, Hydnotrya. To test this hypothesis, we developed a sensitive analytical derivatization method for the detection of gyromitrin using 2,4-dinitrobenzaldehyde as the derivatization reagent. In total, we analyzed 66 specimens for the presence of gyromitrin over 105 tests. Moreover, we sequenced the nuc rDNA internal transcribed spacer region ITS1-5.8S-ITS2 (ITS barcode) and nuc 28S rDNA to assist in species identification and to infer a supporting phylogenetic tree. We detected gyromitrin in all tested specimens from the G. esculenta group as well as G. leucoxantha. This distribution is consistent with a model of rapid evolution coupled with horizontal transfer, which is typical for secondary metabolites. We clarified that gyromitrin production in Discinaceae is both discontinuous and more limited than previously thought. Further research is required to elucidate the gyromitrin biosynthesis gene cluster and its evolutionary history in lorchels.
Asunto(s)
Acetaldehído , Filogenia , Cromatografía Líquida de Alta Presión , ADN Ribosómico/genética , ADN Espaciador Ribosómico/genéticaRESUMEN
The antibiotic-resistant bacteria-associated infections are a major global healthcare threat. New classes of antimicrobial compounds are urgently needed as the frequency of infections caused by multidrug-resistant microbes continues to rise. Recent metagenomic data have demonstrated that there is still biosynthetic potential encoded in but transcriptionally silent in cultivatable bacterial genomes. However, the culture conditions required to identify and express silent biosynthetic gene clusters that yield natural products with antimicrobial activity are largely unknown. Here, we describe a new antibiotic discovery scheme, dubbed the modified crowded plate technique (mCPT), that utilizes complex microbial interactions to elicit antimicrobial production from otherwise silent biosynthetic gene clusters. Using the mCPT as part of the antibiotic crowdsourcing educational program Tiny EarthTM, we isolated over 1400 antibiotic-producing microbes, including 62 showing activity against multidrug-resistant pathogens. The natural product extracts generated from six microbial isolates showed potent activity against vancomycin-intermediate resistant Staphylococcus aureus. We utilized a targeted approach that coupled mass spectrometry data with bioactivity, yielding a new macrolactone class of metabolite, desertomycin H. In this study, we successfully demonstrate a concept that significantly increased our ability to quickly and efficiently identify microbes capable of the silent antibiotic production.
Asunto(s)
Antibacterianos/química , Organismos Acuáticos/química , Macrólidos/química , Animales , Colaboración de las MasasRESUMEN
MicroRNAs (miRNAs) are a family of small noncoding RNAs that regulate gene expression. Due to their important activity in the fine-tuning of protein translation, abnormal expression of miRNAs has been linked to many human diseases, making the targeting of miRNAs attractive as a novel therapeutic strategy. Accordingly, researchers have been heavily engaged in the discovery of small molecule modulators of miRNAs. With an interest in the identification of new chemical space for targeting miRNAs, we developed a high-throughput screening (HTS) technology, catalytic enzyme-linked click chemistry assay (cat-ELCCA), aimed at the discovery of small molecule ligands for pre-miR-21, a miRNA that is frequently overexpressed in human cancers. From our HTS campaign, we found that natural products, a source of many impactful human medicines, may be a promising source of potential pre-miR-21-selective maturation inhibitors. Herein we describe our first efforts in natural product inhibitor discovery leading to the identification of a depsipeptide class of natural products as RNA-binding inhibitors of Dicer-mediated miRNA processing.
RESUMEN
Fluids exhibiting non-Newtonian rheologies are used in a range of applications, including hydraulic fracturing, enhanced oil recovery, remediation, and industrial processes. Hydraulic fracturing in particular has received attention from environmental scientists, policy-makers, and the general public due in part to concerns about the possibility of contamination of groundwater resources by the complex and potentially harmful fluids used in the process. The non-Newtonian nature of many hydraulic fracturing fluids complicates the prediction of their movement, and precludes use of most traditional flow and transport models. To improve understanding of the flow of such fluids in porous media, a series of column experiments was conducted and a pore-scale lattice Boltzmann model (LBM) was developed, verified, and used to simulate analogous systems. Flow experiments were conducted with guar gum solutions of varying concentration and three porous media systems. The LBM was developed for transient, three-dimensional porous medium systems and included a shear rate-dependent dynamic viscosity based on the Cross rheological model. The LBM was verified using a semi-analytical solution for Cross model fluid flow, OpenFOAM simulations, and grid resolution inter-comparisons between two different solution approaches. Simulations were performed on synthetic porous medium systems produced with a sphere packing algorithm to approximate the properties of the experimental systems. The simulations were in good agreement with the experimental results, particularly for systems that exhibited the greatest non-Newtonian character. The modeling approach developed in this work provides a valuable tool for investigating relationships between pore-scale fluid flow and macroscale variables of interest for simulating movement of non-Newtonian fluids at larger scales.
Asunto(s)
Agua Subterránea , Porosidad , Reología , ViscosidadRESUMEN
Phosphopantetheine is a key structural element in biological acyl transfer reactions found embedded within coenzyme A (CoA). Phosphopantothenoylcysteine synthetase (PPCS) is responsible for installing a cysteamine group within phosphopantetheine. Therefore, it holds considerable potential as a drug target for developing new antimicrobials. In this study, we adapted a biochemical assay specific for bacterial PPCS to screen for inhibitors of CoA biosynthesis against a library of marine microbial derived natural product extracts (NPEs). Analysis of the NPE derived from Streptomyces blancoensis led to the isolation of novel antibiotics (10-12, and 14) from the adipostatin class of molecules. The most potent molecule (10) displayed in vitro activity with IC50= 0.93 µM, against S. pneumoniae PPCS. The whole cell antimicrobial assay against isolated molecules demonstrated their ability to penetrate bacterial cells and inhibit clinically relevant pathogenic strains. This establishes the validity of PPCS as a pertinent drug target, and the value of NPEs to provide new antibiotics.
RESUMEN
High-throughput screening and activity-guided purification identified nicoyamycin A, a natural product comprised of an uncommon 3-methyl-1,4-dioxane ring incorporated into a desferrioxamine-like backbone via a spiroaminal linkage. Nicoyamycin A potently inhibits uropathogenic Escherichia coli growth in low iron medium, a promising step toward developing novel antibiotics to treat recalcitrant bacterial infections.
Asunto(s)
Antibacterianos/farmacología , Productos Biológicos/farmacología , Deferoxamina/farmacología , Dioxanos/farmacología , Descubrimiento de Drogas , Infecciones por Escherichia coli/tratamiento farmacológico , Hierro/farmacología , Compuestos de Espiro/farmacología , Escherichia coli Uropatógena/efectos de los fármacos , Antibacterianos/química , Antibacterianos/aislamiento & purificación , Productos Biológicos/química , Productos Biológicos/aislamiento & purificación , Deferoxamina/química , Deferoxamina/aislamiento & purificación , Dioxanos/química , Dioxanos/aislamiento & purificación , Relación Dosis-Respuesta a Droga , Infecciones por Escherichia coli/microbiología , Ensayos Analíticos de Alto Rendimiento , Hierro/química , Pruebas de Sensibilidad Microbiana , Estructura Molecular , Compuestos de Espiro/química , Compuestos de Espiro/aislamiento & purificación , Relación Estructura-Actividad , Escherichia coli Uropatógena/crecimiento & desarrolloRESUMEN
Polyketide synthases (PKSs) represent a powerful catalytic platform capable of effecting multiple carbon-carbon bond forming reactions and oxidation state adjustments. We explored the functionality of two terminal PKS modules that produce the 16-membered tylosin macrocycle, using them as biocatalysts in the chemoenzymatic synthesis of tylactone and its subsequent elaboration to complete the first total synthesis of the juvenimicin, M-4365, and rosamicin classes of macrolide antibiotics via late-stage diversification. Synthetic chemistry was employed to generate the tylactone hexaketide chain elongation intermediate that was accepted by the juvenimicin (Juv) ketosynthase of the penultimate JuvEIV PKS module. The hexaketide is processed through two complete modules (JuvEIV and JuvEV) in vitro, which catalyze elongation and functionalization of two ketide units followed by cyclization of the resulting octaketide into tylactone. After macrolactonization, a combination of in vivo glycosylation, selective in vitro cytochrome P450-mediated oxidation, and chemical oxidation was used to complete the scalable construction of a series of macrolide natural products in as few as 15 linear steps (21 total) with an overall yield of 4.6%.
Asunto(s)
Antibacterianos/biosíntesis , Macrólidos/metabolismo , Sintasas Poliquetidas/metabolismo , Policétidos/metabolismo , Tilosina/análogos & derivados , Antibacterianos/química , Antibacterianos/farmacología , Biocatálisis , Relación Dosis-Respuesta a Droga , Bacterias Gramnegativas/efectos de los fármacos , Bacterias Grampositivas/efectos de los fármacos , Macrólidos/química , Macrólidos/farmacología , Pruebas de Sensibilidad Microbiana , Conformación Molecular , Sintasas Poliquetidas/química , Policétidos/química , Policétidos/farmacología , Relación Estructura-Actividad , Tilosina/biosíntesis , Tilosina/química , Tilosina/farmacologíaRESUMEN
Pathogenic microorganisms often have the ability to attach to a surface, building a complex matrix where they colonize to form a biofilm. This cellular superstructure can display increased resistance to antibiotics and cause serious, persistent health problems in humans. Here we describe a high-throughput in vitro screen to identify inhibitors of Acinetobacter baumannii biofilms using a library of natural product extracts derived from marine microbes. Analysis of extracts derived from Streptomyces gandocaensis results in the discovery of three peptidic metabolites (cahuitamycins A-C), with cahuitamycin C being the most effective inhibitor (IC50=14.5 µM). Biosynthesis of cahuitamycin C proceeds via a convergent biosynthetic pathway, with one of the steps apparently being catalysed by an unlinked gene encoding a 6-methylsalicylate synthase. Efforts to assess starter unit diversification through selective mutasynthesis lead to production of unnatural analogues cahuitamycins D and E of increased potency (IC50=8.4 and 10.5 µM).
Asunto(s)
Acinetobacter baumannii/efectos de los fármacos , Antibacterianos/farmacología , Proteínas Bacterianas/farmacología , Biopelículas/efectos de los fármacos , Oligopéptidos/farmacología , Acinetobacter baumannii/fisiología , Antibacterianos/biosíntesis , Proteínas Bacterianas/biosíntesis , Vías Biosintéticas , Ensayos Analíticos de Alto Rendimiento , Oligopéptidos/biosíntesis , StreptomycesRESUMEN
TB medication completion treatment rates for active TB patients living in impoverished US-Mexico border communities called colonias in southern New Mexico counties are unknown. It might be suspected that residents of colonias have lower completion rates than those living in incorporated and medically more accessible areas. A retrospective record review of closed TB case records from 1993 to 2010 of southern New Mexico border counties, was conducted using a modified version of the New Mexico Department of Health Tuberculosis Targeted Health Assessment/History form (Appendix 1). Study findings reveal that despite their unincorporated status, poorer living conditions and questionable legal status, colonia TB patients had a higher medication completion rate than their non-colonia counterparts. A robust New Mexico TB treatment program contributed to high completion rates with death being the number-one reason for treatment non-completion in both colonia and non-colonias.
Asunto(s)
Antituberculosos/administración & dosificación , Cumplimiento de la Medicación/estadística & datos numéricos , Cooperación del Paciente/estadística & datos numéricos , Tuberculosis/tratamiento farmacológico , Tuberculosis/epidemiología , Adulto , Factores de Edad , Anciano , Bases de Datos Factuales , Femenino , Humanos , Modelos Logísticos , Masculino , Cumplimiento de la Medicación/etnología , Persona de Mediana Edad , New Mexico , Pobreza , Valor Predictivo de las Pruebas , Estudios Retrospectivos , Medición de Riesgo , Factores Sexuales , Análisis de Supervivencia , Tuberculosis/diagnóstico , Adulto JovenRESUMEN
Methods to identify the bioactive diversity within natural product extracts (NPEs) continue to evolve. NPEs constitute complex mixtures of chemical substances varying in structure, composition, and abundance. NPEs can therefore be challenging to evaluate efficiently with high-throughput screening approaches designed to test pure substances. Here we facilitate the rapid identification and prioritization of antimalarial NPEs using a pharmacologically driven, quantitative high-throughput-screening (qHTS) paradigm. In qHTS each NPE is tested across a concentration range from which sigmoidal response, efficacy, and apparent EC50s can be used to rank order NPEs for subsequent organism reculture, extraction, and fractionation. Using an NPE library derived from diverse marine microorganisms we observed potent antimalarial activity from two Streptomyces sp. extracts identified from thousands tested using qHTS. Seven compounds were isolated from two phylogenetically related Streptomyces species: Streptomyces ballenaensis collected from Costa Rica and Streptomyces bangulaensis collected from Papua New Guinea. Among them we identified actinoramides A and B, belonging to the unusually elaborated nonproteinogenic amino-acid-containing tetrapeptide series of natural products. In addition, we characterized a series of new compounds, including an artifact, 25-epi-actinoramide A, and actinoramides D, E, and F, which are closely related biosynthetic congeners of the previously reported metabolites.
Asunto(s)
Antimaláricos/aislamiento & purificación , Antimaláricos/farmacología , Productos Biológicos/aislamiento & purificación , Productos Biológicos/farmacología , Oligopéptidos/aislamiento & purificación , Oligopéptidos/farmacología , Streptomyces/química , Antimaláricos/química , Productos Biológicos/química , Costa Rica , Sedimentos Geológicos/química , Biología Marina , Estructura Molecular , Resonancia Magnética Nuclear Biomolecular , Oligopéptidos/química , Papúa Nueva Guinea , Filogenia , Plasmodium falciparum/efectos de los fármacos , Streptomyces/genéticaRESUMEN
As part of the International Cooperative Biodiversity Groups (ICBG) Program, we were interested in identifying biologically active unfolded protein response (UPR) inducing compounds from marine microorganisms isolated from Costa Rican biota. With this aim in mind we have now generated more than 33,000 unique prefractionated natural product extracts from marine and terrestrial organisms that have been submitted to the Center of Chemical Genomics (CCG) at the University of Michigan for high throughput screening (HTS). An effective complementary cell-based assay to identify novel modulators of UPR signaling was used for screening extracts. Active fractions were iteratively subjected to reverse-phase HPLC chromatographic analysis, and together with lobophorin A, B, E, and F (1-4), three new lobophorin congeners, designated as CR1 (5), CR2 (6), and CR3 (7) were isolated. Herein, we report that secondary assays revealed that the new lobophorins induced UPR-associated gene expression, inhibited oral squamous cell carcinoma cell growth, and led to UPR-dependent cell death in murine embryonic fibroblast (MEF) cells.
RESUMEN
Novel antimicrobials that effectively inhibit bacterial growth are essential to fight the growing threat of antibiotic resistance. A promising target is the bacterial ribosome, a 2.5 MDa organelle susceptible to several biorthogonal modes of action used by different classes of antibiotics. To promote the discovery of unique inhibitors, we have miniaturized a coupled transcription/translation assay using E. coli and applied it to screen a natural product library of ~30 000 extracts. We significantly reduced the scale of the assay to 2 µL in a 1536-well plate format and decreased the effective concentration of costly reagents. The improved assay returned 1327 hits (4.6% hit rate) with %CV and Z' values of 8.5% and 0.74, respectively. This assay represents a significant advance in molecular screening, both in miniaturization and its application to a natural product extract library, and we intend to apply it to a broad array of pathogenic microbes in the search for novel anti-infective agents.
Asunto(s)
Productos Biológicos/farmacología , Evaluación Preclínica de Medicamentos/métodos , Ensayos Analíticos de Alto Rendimiento/métodos , Antiinfecciosos/farmacología , Escherichia coli/efectos de los fármacos , Escherichia coli/genética , Luciferasas/genética , Miniaturización/métodos , Biosíntesis de Proteínas/efectos de los fármacos , Ribosomas/efectos de los fármacos , Ribosomas/genética , Bibliotecas de Moléculas Pequeñas , Transcripción Genética/efectos de los fármacosRESUMEN
Alphaviruses are a prominent class of reemergent pathogens due to their globally expanding ranges, potential for lethality, and possible use as bioweapons. The absence of effective treatments for alphaviruses highlights the need for innovative strategies to identify antiviral agents. Primary screens that use noninfectious self-replicating RNAs, termed replicons, have been used to identify potential antiviral compounds for alphaviruses. Only inhibitors of viral genome replication, however, will be identified using replicons, which excludes many other druggable steps in the viral life cycle. To address this limitation, we developed a western equine encephalitis virus pseudoinfectious particle system that reproduces several crucial viral life cycle steps in addition to genome replication. We used this system to screen a library containing ~26,000 extracts derived from marine microbes, and we identified multiple bacterial strains that produce compounds with potential antiviral activity. We subsequently used pseudoinfectious particle and replicon assays in parallel to counterscreen candidate extracts, and followed antiviral activity during biochemical fractionation and purification to differentiate between inhibitors of viral entry and genome replication. This novel process led to the isolation of a known alphavirus entry inhibitor, bafilomycin, thereby validating the approach for the screening and identification of potential antiviral compounds.
Asunto(s)
Alphavirus/efectos de los fármacos , Alphavirus/fisiología , Antivirales/farmacología , Productos Biológicos/farmacología , Descubrimiento de Drogas/métodos , Animales , Antivirales/química , Productos Biológicos/química , Línea Celular , Relación Dosis-Respuesta a Droga , Ensayos Analíticos de Alto Rendimiento , Humanos , Concentración 50 Inhibidora , Pruebas de Sensibilidad Microbiana/métodos , Reproducibilidad de los Resultados , Bibliotecas de Moléculas Pequeñas , Replicación Viral/efectos de los fármacosRESUMEN
Biochemical high-throughput screening is widely used in drug discovery, using a variety of small molecule libraries. However, broader screening strategies may be more beneficial to identify novel biologic mechanisms. In the current study we used a ß-galactosidase complementation method to screen a selection of microbial-derived pre-fractionated natural product extracts for those that increase regulator of G protein signaling 2 (RGS2) protein levels. RGS2 is a member of a large family of proteins that all regulate signaling through G protein-coupled receptors (GPCRs) by accelerating GTPase activity on active Gα as well as through other mechanisms. RGS2(-/-) mice are hypertensive, show increased anxiety, and are prone to heart failure. RGS2 has a very short protein half-life due to rapid proteasomal degradation, and we propose that enhancement of RGS2 protein levels could be a beneficial therapeutic strategy. Bioassay-guided fractionation of one of the hit strains yielded a pure compound, Indolactam V, a known protein kinase C (PKC) activator, which selectively increased RGS2 protein levels in a time- and concentration-dependent manner. Similar results were obtained with phorbol 12-myristate 13-acetate as well as activation of the Gq-coupled muscarinic M3 receptor. The effect on RGS2 protein levels was blocked by the nonselective PKC inhibitor Gö6983 (3-[1-[3-(dimethylamino)propyl]-5-methoxy-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione), the PKCß-selective inhibitor Ruboxastaurin, as well as small interfering RNA-mediated knockdown of PKCß. Indolactam V-mediated increases in RGS2 protein levels also had functional effects on GPCR signaling. This study provides important proof-of-concept for our screening strategy and could define a negative feedback mechanism in Gq/Phospholipase C signaling through RGS2 protein upregulation.
Asunto(s)
Productos Biológicos/farmacología , Indoles/farmacología , Lactamas/farmacología , Proteína Quinasa C beta/efectos de los fármacos , Proteínas RGS/metabolismo , Bibliotecas de Moléculas Pequeñas/farmacología , Regulación hacia Arriba , Actinobacteria/química , Animales , Células HEK293 , Ensayos Analíticos de Alto Rendimiento , Humanos , Maleimidas/farmacología , Miocitos del Músculo Liso/efectos de los fármacos , Fenotipo , Proteína Quinasa C beta/antagonistas & inhibidores , Proteína Quinasa C beta/metabolismo , Inhibidores de Proteínas Quinasas/farmacología , Proteínas RGS/genética , Ratas , Receptor Muscarínico M3/agonistas , Acetato de Tetradecanoilforbol/farmacologíaRESUMEN
Proteins with expanded polyglutamine (polyQ) segments cause a number of fatal neurodegenerative disorders, including Huntington's disease (HD). Previous high-throughput screens in cellular and biochemical models of HD have revealed compounds that mitigate polyQ aggregation and proteotoxicity, providing insight into the mechanisms of disease and leads for potential therapeutics. However, the structural diversity of natural products has not yet been fully mobilized toward these goals. Here, we have screened a collection of ~11 000 natural product extracts for the ability to recover the slow growth of ΔProQ103-expressing yeast cells in 384-well plates (Z' ~ 0.7, CV ~ 8%). This screen identified actinomycin D as a strong inhibitor of polyQ aggregation and proteotoxicity at nanomolar concentrations (~50-500 ng/mL). We found that a low dose of actinomycin D increased the levels of the heat-shock proteins Hsp104, Hsp70 and Hsp26 and enhanced binding of Hsp70 to the polyQ in yeast. Actinomycin also suppressed aggregation of polyQ in mammalian cells, suggesting a conserved mechanism. These results establish natural products as a rich source of compounds with interesting mechanisms of action against polyQ disorders.
Asunto(s)
Productos Biológicos/química , Ensayos Analíticos de Alto Rendimiento , Modelos Biológicos , Péptidos/genética , Animales , Productos Biológicos/análisis , Dactinomicina/farmacología , Regulación de la Expresión Génica/efectos de los fármacos , Humanos , Células PC12 , Péptidos/química , Agregación Patológica de Proteínas/tratamiento farmacológico , Ratas , Saccharomyces cerevisiaeRESUMEN
Siderophores are high-affinity iron chelators produced by microorganisms and frequently contribute to the virulence of human pathogens. Targeted inhibition of the biosynthesis of siderophores staphyloferrin B of Staphylococcus aureus and petrobactin of Bacillus anthracis hold considerable potential as a single or combined treatment for methicillin-resistant S. aureus (MRSA) and anthrax infection, respectively. The biosynthetic pathways for both siderophores involve a nonribosomal peptide synthetase independent siderophore (NIS) synthetase, including SbnE in staphyloferrin B and AsbA in petrobactin. In this study, we developed a biochemical assay specific for NIS synthetases to screen for inhibitors of SbnE and AsbA against a library of marine microbial-derived natural product extracts (NPEs). Analysis of the NPE derived from Streptomyces tempisquensis led to the isolation of the novel antibiotics baulamycins A (BmcA, 6) and B (BmcB, 7). BmcA and BmcB displayed in vitro activity with IC50 values of 4.8 µM and 19 µM against SbnE and 180 µM and 200 µM against AsbA, respectively. Kinetic analysis showed that the compounds function as reversible competitive enzyme inhibitors. Liquid culture studies with S. aureus , B. anthracis , E. coli , and several other bacterial pathogens demonstrated the capacity of these natural products to penetrate bacterial barriers and inhibit growth of both Gram-positive and Gram-negative species. These studies provide proof-of-concept that natural product inhibitors targeting siderophore virulence factors can provide access to novel broad-spectrum antibiotics, which may serve as important leads for the development of potent anti-infective agents.
Asunto(s)
Antibacterianos/farmacología , Bacillus anthracis/efectos de los fármacos , Productos Biológicos/farmacología , Daunorrubicina/análogos & derivados , Escherichia coli/efectos de los fármacos , Sideróforos/antagonistas & inhibidores , Staphylococcus aureus/efectos de los fármacos , Antibacterianos/química , Antibacterianos/aislamiento & purificación , Bacillus anthracis/química , Bacillus anthracis/metabolismo , Productos Biológicos/química , Productos Biológicos/aislamiento & purificación , Daunorrubicina/síntesis química , Daunorrubicina/química , Daunorrubicina/farmacología , Relación Dosis-Respuesta a Droga , Ensayos Analíticos de Alto Rendimiento , Pruebas de Sensibilidad Microbiana , Conformación Molecular , Sideróforos/biosíntesis , Staphylococcus aureus/química , Staphylococcus aureus/metabolismo , Relación Estructura-ActividadRESUMEN
Natural products provide a vast array of chemical structures to explore in the discovery of new medicines. Although secondary metabolites produced by microbes have been developed to treat a variety of diseases, including bacterial and fungal infections, to date there has been limited investigation of natural products with antiviral activity. In this report, we used a phenotypic cell-based replicon assay coupled with an iterative biochemical fractionation process to identify, purify, and characterize antiviral compounds produced by marine microbes. We isolated a compound from Streptomyces kaviengensis, a novel actinomycetes isolated from marine sediments obtained off the coast of New Ireland, Papua New Guinea, which we identified as antimycin A1a. This compound displays potent activity against western equine encephalitis virus in cultured cells with half-maximal inhibitory concentrations of less than 4 nM and a selectivity index of greater than 550. Our efforts also revealed that several antimycin A analogues display antiviral activity, and mechanism of action studies confirmed that these Streptomyces-derived secondary metabolites function by inhibiting the cellular mitochondrial electron transport chain, thereby suppressing de novo pyrimidine synthesis. Furthermore, we found that antimycin A functions as a broad spectrum agent with activity against a wide range of RNA viruses in cultured cells, including members of the Togaviridae, Flaviviridae, Bunyaviridae, Picornaviridae, and Paramyxoviridae families. Finally, we demonstrate that antimycin A reduces central nervous system viral titers, improves clinical disease severity, and enhances survival in mice given a lethal challenge with western equine encephalitis virus. Our results provide conclusive validation for using natural product resources derived from marine microbes as source material for antiviral drug discovery, and they indicate that host mitochondrial electron transport is a viable target for the continued development of broadly active antiviral compounds.
Asunto(s)
Actinobacteria/química , Antivirales/farmacología , Sedimentos Geológicos/microbiología , Animales , Antimicina A/química , Antimicina A/farmacología , Antimicina A/uso terapéutico , Antivirales/química , Antivirales/aislamiento & purificación , Productos Biológicos/química , Productos Biológicos/aislamiento & purificación , Productos Biológicos/farmacología , Línea Celular , Sistema Nervioso Central/efectos de los fármacos , Sistema Nervioso Central/patología , Sistema Nervioso Central/virología , Fraccionamiento Químico , Transporte de Electrón/efectos de los fármacos , Virus de la Encefalitis/efectos de los fármacos , Encefalitis por Arbovirus/tratamiento farmacológico , Encefalitis por Arbovirus/patología , Encefalitis por Arbovirus/virología , Ensayos Analíticos de Alto Rendimiento , Humanos , Ratones , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , ARN Viral/metabolismo , Estándares de Referencia , Reproducibilidad de los Resultados , Streptomyces/química , Análisis de Supervivencia , Transcripción Genética/efectos de los fármacosRESUMEN
BACKGROUND: About half of all pregnancies in the United States are unplanned, and many start soon after a previous delivery. Our aim was to determine if the implementation of the Quick Start Contraception Initiation Method during the 6-week postpartum evaluation could improve the delivery of contraception. STUDY DESIGN: The medical records of 979 patients seen for their 6-week postpartum visit at our urban Federally Qualified Health Center (FQHC) between July 2004 and June 2006 were reviewed. The patients were distributed into two groups defined by evaluations performed prior to or after the implementation of the new contraception initiation method. Summary statistics and differences in the proportions were calculated. A probability of <.05 was considered significant. RESULTS: The Quick Start Contraception Initiation Method was implemented in July 2005. Five-hundred and sixteen patients were in Group 1, and 463 patients were in Group 2. Demographic variables were similar among groups. Contraception delivery rate was 50% in Group 1 and 72% in Group 2 (p<.05). Eighty percent of patients in Group 1 and 76% of those in Group 2 requested contraception, and 26% of Group 1 and 3% of Group 2 did not receive it. The improvement in dispensing contraception was most noticeable among teenagers. CONCLUSION: These findings suggest that the Quick Start Contraception Initiation Method at the time of the 6-week postpartum evaluation improves the delivery of contraception in FQHCs.